Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2020-09-28 Capital/Financing Update
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Appendix 3G 12 pages 208.5KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3G form submitted to the ASX (Australian Securities Exchange) regarding the notification of issue, conversion, or payment up of equity securities. It details the issuance of securities under an employee incentive scheme, including the number of securities, the recipients (key management personnel), and the terms of the securities. The document is a regulatory announcement about changes in the company's capital structure, specifically the issuance of new equity securities. It is not a full financial report, earnings release, or management discussion. It fits the category of announcements related to capital changes or financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2020-09-28 English
Appendix 3G 41 pages 702.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an announcement dated 22 September 2020 from Mayne Pharma Group Limited regarding the issuance of new employee options and performance rights. It includes detailed information about the number and terms of securities issued under an employee incentive scheme, referencing Appendix 3G, which is a standard ASX form for notifying the issue of securities. The content focuses on the issuance of equity securities to employees and management, including key management personnel, and the terms of vesting and performance hurdles. There is no financial performance data, earnings information, or management discussion of results. The document is a regulatory announcement about a capital change related to employee incentives, not a full report or financial statement. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2020-09-21 English
Change of Director's Interest Notice 2 pages 190.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the transaction, the nature of the transaction (on-market trade), and dates. There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a director's personal share transactions, which fits the definition of 'Director's Dealing' filings. The document length is 3239 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the correct classification is 'DIRS' (Director's Dealing).
2020-09-01 English
Change of Director's Interest Notice 2 pages 194.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the change, and related contract interests. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial statements or company performance data, nor is it an announcement of a report or a certification. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 4016 characters, which is consistent with a detailed insider trading notice rather than a full financial report or announcement.
2020-08-31 English
Ceasing to be a substantial holder 4 pages 528.4KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 605 Notice of ceasing to be a substantial holder under the Corporations Act 2001, Section 671B. It details changes in relevant interests and associations related to substantial shareholding in Mayne Pharma Group Limited. This type of filing is a notification about changes in significant share ownership levels, specifically ceasing to be a substantial holder. It is not a financial report, earnings release, or management report, but a regulatory notification about shareholding status. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length and content confirm it is a substantive notice, not a brief announcement or certification.
2020-08-24 English
Change in substantial holding 7 pages 921.1KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 604' and is a 'Notice of change of interests of substantial holder' under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder, Lazard Asset Management Pacific Co, including annexures listing associates and specific share transactions. This type of filing is a notification of changes in significant share ownership levels, which corresponds to the category 'Major Shareholding Notification'. The document is not a financial report, earnings release, or management report, but a regulatory disclosure about shareholding changes.
2020-08-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.